logo
Share SHARE
FONT-SIZE Plus   Neg

Foundation Medicine And Clovis Oncology Enter Into Diagnostic Collaboration

Foundation Medicine Inc. and Clovis Oncology Inc. (CLVS) announced that they have entered into a diagnostic collaboration. The company said that the goal of the collaboration is to develop an in-vitro diagnostic or IVD to identify biomarkers to select cancer patients most likely to respond to Clovis' product candidate rucaparib, a poly (ADP-ribose) polymerase or PARP inhibitor currently in Phase I/II clinical development.

Clovis Oncology said that the company and Foundation Medicine will analyze the genomic alterations found in tissue samples from patients to evaluate the feasibility of developing an IVD method to identify patients who have tumors more likely to respond to rucaparib.

In particular, the goal of the collaboration is to identify the additional genetic mutations beyond those in germ-line and somatic BRCA that are associated with defective DNA repair and may define appropriate tumor targets for rucaparib.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Palo Alto Networks, Inc. (PANW) shares are down about 7%, but we think the stock is overreacting. We believe the tidings are not all that bad. Quarterly results and guidance are a mixed bag, in fact. Watch the slide show for more details. Mortgage application volume rose last week, ending two straight weeks of declines, as interest rates held steady. The Market Composite Index, a measure of mortgage loan application volume, increased 2.8 percent on a seasonally adjusted basis for the week ending August 26, from one week earlier, according to the Mortgage Bankers Association or MBA. As part of the launch of "Rogue One: A Star Wars Story," a new toyline was unveiled on Wednesday in a stop motion video created by fans. A series of original animated shorts from Star-war fans starring key toys were used to create the video.
comments powered by Disqus
Follow RTT